Bioequivalence of a new formulation of omalizumab, solution for injection in prefilled syringe, to the current lyophilized formulation Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009
A novel submicron budesonide suspension demonstrates equivalent nebulization times compared to cyclodextrin-based solution formulations Source: Annual Congress 2008 - Wheezing in preschool children Year: 2008
Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001
A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Development of a powder for inhalation with R,R-Glycopyrrolate as active ingredient for the delivery from a novel multidose dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 471s Year: 2003
Comparison of systemic bioavailability of two formulations of budesonide nebulized suspension in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Effect of device and formulation on delivery of budesonide suspensions by nebulizers Source: Eur Respir J 2002; 20: Suppl. 38, 542s Year: 2002
A new nonultra fine BDP HFA 134a formulation: clinical equivalence of efficacy and safety versus CFC formulation Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Estimation of efficiency of new combined preparation built-in-liposomes budesonide compared with water budesonide suspension Source: Eur Respir J 2004; 24: Suppl. 48, 83s Year: 2004
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001
Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007
Clinical equivalence of budesonide delivered via two dry powder inhalers Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
In-use in vitro performance of formoterol fumarate dihydrate powder for inhalation (6 and 12 µg/dose) delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R) Source: Eur Respir J 2001; 17: 1332-1333 Year: 2001
Stability of a new formulation of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Formoterol: a new pMDI CFC free formulation. Efficacy of the 12µg dosage versus a dry powder inhaler in moderate to severe asthmatic patients Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
Equivalence testing of salbutamol dry powder inhalers by in vitro impaction Source: Eur Respir J 2001; 18: Suppl. 33, 100s Year: 2001
Pharmaceutical development of a liquid formulation for pulmonary application of a peptide Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012